Browse our anti-VEGFR2 (KDR) Antibodies

Human Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. VEGF (show VEGFA Antibodies), VEGFR2 and GSTM1 (show GSTM1 Antibodies) polymorphisms in outcome of multiple myeloma patients treated with thalidomide-based regimens

2. In the in vitro tests, JFD-WS effectively inhibited HUVEC proliferation, migration, tube formation and VEGFR2 phosphorylation. Additionally, JFD-WS inhibited the formation of blood vessels in chick chorioallantoic membrane. While inhibiting the xenograft tumor growth in experimental mice, JFD-WS decreased the plasma MUC1 (show MUC1 Antibodies) levels

3. The effects of Platelet-rich plasma on vascular endothelial growth factor receptor-2 (VEGFR2) and CD34 (show CD34 Antibodies) expression were evaluated using real-time PCR, flow cytometry, western blot, immunocytochemistry and pathological study, as were carried out in both human umbilical endothelial cell culture and rat skin

4. metformin's dual effect in hyperglycemia-chemical hypoxia is mediated by direct effect on VEGFR1 (show FLT1 Antibodies)/R2 leading to activation of cell migration through MMP16 (show MMP16 Antibodies) and ROCK1 (show ROCK1 Antibodies) upregulation, and inhibition of apoptosis by increase in phospho-ERK1/2 and FABP4 (show FABP4 Antibodies), components of VEGF (show VEGFA Antibodies) signaling cascades

5. Single nucleotide polymorphism of VEGFR2 is associated with relapse in gastroenteropancreatic neuroendocrine neoplasms.

6. Our data showed that ampelopsin inhibited angiogenesis with no cytotoxicity by suppressing both VEGFR2 signaling and HIF-1alpha (show HIF1A Antibodies) expression. These results suggest that Hovenia dulcis Thunb. and its active compound ampelopsin exhibit potent antiangiogenic activities and therefore could be valuable for the prevention and treatment of angiogenesis-related diseases including cancer.

7. Authors demonstrated that when VEGFR2 was inhibited, NRP-1 (show NELL1 Antibodies) appeared to regulate RAD51 (show RAD51 Antibodies) expression through the VEGFR2-independent ABL-1 (show ABL1 Antibodies) pathway, consequently regulating radiation sensitivity. In addition, the combined inhibition of VEGFR2 and NRP-1 (show NELL1 Antibodies) appears to sensitize cancer cells to radiation.

8. We found that depletion of FGD5 (show FGD5 Antibodies) in microvascular cells inhibited their migration towards a stable VEGFA (show VEGFA Antibodies) gradient. Furthermore, depletion of FGD5 (show FGD5 Antibodies) resulted in accelerated VEGFR2 degradation, which was reverted by lactacystin-mediated proteasomal inhibition. Our results thus suggest a mechanism whereby FGD5 (show FGD5 Antibodies) sustains VEGFA (show VEGFA Antibodies) signaling and endothelial cell chemotaxis via inhibition of proteasome-dependent VEGFR2 degradation.

9. ATG5 (show ATG5 Antibodies) and phospho-KDR expression was strongly associated with the density of vasculogenic mimicry in tumors and poor clinical outcome.

10. Increased expression of VEGFR2 correlated with differentiation.

Mouse (Murine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. Inositol 1,4,5-trisphosphate receptors (IP3Rs) are required for the hematopoietic and cardiac fate divergence of mouse embryonic stem cells. Deletion of IP3Rs (IP3R (show ITPR1 Antibodies)-tKO (show MRPS12 Antibodies)) reduced Flk1+/PDGFRalpha- hematopoietic mesoderm, c-Kit (show KIT Antibodies)+/CD41+ hematopoietic progenitor cell population, and the colony-forming unit activity, but increased cardiac progenitor markers as well as cardiomyocytes.

2. Peli1 (show PELI1 Antibodies) is a proangiogenic molecule that acts downstream of VEGF (show VEGFA Antibodies)-Flk-1 and restores angiogenesis and enhances skin flap (show ALOX5AP Antibodies) survivability

3. KDR/Flk-1 expression was revealed in mononuclear cells of the necrotic area (macrophages and fibroblast cells). The distribution of KDR/Flk-1 remained practically unchanged with lengthening of the postinfarction period (more than 7 days).

4. By E10.5, both Sox7 (show SOX7 Antibodies) complete knockout and FLK1-specific deletion of Sox7 (show SOX7 Antibodies) lead to widespread vascular defects. In contrast, while SOX7 (show SOX7 Antibodies) is expressed in the earliest specified blood progenitors, the VAV (show VAV1 Antibodies)-specific deletion of Sox7 (show SOX7 Antibodies) does not affect the hematopoietic system. Together, our data reveal the unique role of SOX7 (show SOX7 Antibodies) in vasculogenesis and angiogenesis during embryonic development.

5. JAM-C (show JAM3 Antibodies) plays an important role in maintaining VEGR2 expression to promote retinal pigment epithelial cell survival under oxidative stress.

6. Genetic depletion experiments revealed that VEGFR2, but not VEGFR3 (show FLT4 Antibodies), is indispensable for maintenance of thyroid vascular integrity. Notably, blockade of VEGF-A (show VEGFA Antibodies) or VEGFR2 not only abrogated vascular remodeling but also inhibited follicular hypertrophy, which led to the reduction of thyroid weights during goitrogenesis.

7. Eriocalyxin B inhibited breast tumor angiogenesis by suppressing VEGFR-2 signaling.

8. transgenic mice may serve as valid models for the validation of novel therapies blocking the VEGFR-2 signaling pathway in hemangioma-like lesions and other vascular diseases

9. found that WT1 (show WT1 Antibodies) and KDR are co-expressed in Sertoli cells of the testes and somatic cells of embryonic ovaries. Furthermore, WT1 (show WT1 Antibodies) bound to the Kdr promoter in the chromatin of embryonic testes and ovaries. KDR signaling represses the testis-promoting gene Sox9 (show SOX9 Antibodies) in embryonic XX gonads

10. This is the first report demonstrating the spatiotemporal expression patterns of Flk1 and Flt1 (show FLT1 Antibodies) in the coronary vascular system during development and after MI; thus, this study suggests that these factors have distinct and important functions in coronary angiogenesis.

Pig (Porcine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. Here we demonstrate that VEGF (show VEGFA Antibodies)-165 mediates MSC (show MSC Antibodies) differentiation into ECs via VEGFR-2-dependent induction of Sox18 (show SOX18 Antibodies), which ultimately coordinates the transcriptional upregulation of specific markers of the EC phenotype

2. NOS (show NOS Antibodies) stimulation via PI3K, calpain proteases, and SIRT1 (show SIRT1 Antibodies)-dependent deacetylation downstream from VEGFR2 activation contributes to these vasodilator responses.

3. we analyzed the expression and cellular distribution of Flt-1(VEGFR-1 (show FLT1 Antibodies)) and Flk-1 (KDR/VEGFR-2)in newborn piglet brain

4. expression of FLK1, CD146 (show MCAM Antibodies) and microvessel density of angiogenesis at the first week of reperfused acute myocardial infarction.

5. VEGF (show VEGFA Antibodies) supplementation at the late embryonic developmental stage might improve the developmental potential of both IVF (show SCN5A Antibodies) and somatic nuclear transfer preimplantation porcine embryos through its receptors.

6. The VEGFR2 mRNA was only upregulated in early glomerulogenesis, suggesting that VEGFR2 is important for the vascular growth.

7. increased placental expression of the VEGF receptor (show FLT1 Antibodies) system is associated with increased placental vascular density observed with the advancement of gestation in the pig

8. VEGF (show VEGFA Antibodies) ligand-receptor system may play an important role in the development and maintenance of the corpus luteum in pigs.

9. VEGF (show VEGFA Antibodies)/Flk-1/Flt-1 (show FLT1 Antibodies) system is activated during myocardial ischemia reperfusion injury.

10. Hemodialysis graft placement leads to early increases in wall shear stress, VEGF-A (show VEGFA Antibodies), pro-MMP-9 (show MMP9 Antibodies), MMP-2 (show MMP2 Antibodies), VEGFR-1 (show FLT1 Antibodies), VEGFR-2, and TIMP-1 (show TIMP1 Antibodies), which may contribute to the development of venous stenosis.

Cow (Bovine) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. data for the first time demonstrate a calpain/PTP1B/VEGFR2 negative feedback loop in the regulation of VEGF-induced angiogenesis. Modulation of local PTP1B and/or calpain activities may prove beneficial in the treatment of impaired wound healing in diabetes.

2. endothelial cells exposed to TGF-beta1 (show TGFB1 Antibodies) lose both tip and stalk cell identity, possibly mediated by loss of VEGFR2 signaling.

3. These results suggest that non-dominant follicles maintain a greater concentration of the mRNA expression of both membrane and soluble VEGF (show VEGFA Antibodies) receptors; but follicular dominance is related to a reduction in the mRNA expression of sVEGFR1 and sVEGFR2.

4. Data suggest that galectin-1 (show LGALS1 Antibodies) and VEGFR-2 are expressed at mid-luteal stages in luteal cells of corpus luteum; galectin-1 (show LGALS1 Antibodies) binds directly to asparagine-linked glycans (N-glycans) on VEGFR-2 in luteal cells.

5. MMP-1 (show MMP1 Antibodies) promotes VEGFR2 expression and proliferation of endothelial cells through stimulation of PAR-1 (show F2R Antibodies) and activation of NF-kappaB (show NFKB1 Antibodies)

6. Vascular endothelial growth factor receptor-2 activates ADP-ribosylation factor 1 (show ARF1 Antibodies) to promote endothelial nitric-oxide synthase (show NOS3 Antibodies) activation and nitric oxide release from endothelial cells

7. VEGFR2 mRNA expression was higher at the mid and late luteal stages than at the early I and early II luteal stages, and VEGFR2 protein was higher at the mid and late luteal stages than at estrus (P<0.05)

8. Alterations in the expression of VEGF-A (show VEGFA Antibodies) and bFGF (show FGF2 Antibodies) systems suggest that angiogenic factors are involved in abnormal placental development in cloned gestations, contributing to impaired fetal development and poor survival rates.

9. involved in sphingosine 1-phosphate-stimulated phosphorylation of Akt (show AKT1 Antibodies) and endothelial nitric-oxide synthase (eNOS (show NOS3 Antibodies))

10. Placenta growth factor (show PGF Antibodies) expression is regulated by both VEGF (show VEGFA Antibodies) and hyperglycaemia via VEGFR-2.

Rainbow Trout (Oncorhynchus mykiss) Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. These results indicate that VEGF-C (show VEGFC Antibodies)-induced MSC (show MSC Antibodies) osteogenesis is mediated through VEGFR2 and VEGFR3 (show FLT4 Antibodies), and followed the activation of the ERK (show MAPK1 Antibodies)/RUNX2 (show RUNX2 Antibodies) signaling pathway.

Rabbit Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. High VEGFR2 expression is associated with retinal neovascularization.

2. ghrelin (show GHRL Antibodies) can inhibit intraplaque angiogenesis and promote plaque stability by down-regulating VEGF (show VEGFA Antibodies) and VEGFR2 expression, inhibiting the plaque content of macrophages, and reducing MCP-1 (show CCL2 Antibodies) expression at an advanced stage of atherosclerosis in rabbits

3. Antenatal intratracheal VEGF (show VEGFA Antibodies) administration was associated with an increase in Flk-1 immunoreactivity.

Zebrafish Kinase insert Domain Receptor (A Type III Receptor tyrosine Kinase) (KDR) interaction partners

1. Intronic Flk1 genetic enhancer element directs arterial-specific expression via RBPJ (show RBPJ Antibodies)-mediated venous repression.